Quanta Therapeutics, Inc.

Quanta Therapeutics, Inc. is a biotechnology company based in the US, focused on developing innovative allosteric inhibitors targeting RAS-driven cancers, particularly KRAS mutations. Their mission is to provide effective treatments for challenging cancer types. Founded in 2018 and headquartered in South San Francisco, US, Quanta Therapeutics, Inc.

specializes in developing targeted therapies for RAS-driven cancers. The company has raised a total of USD 50. 68 mn from four funding rounds, with the most recent being a Series D round on May 10, 2023. This round was led by Avidity Partners Management, with participation from several other investors including AbbVie Biotech Ventures and Longitude Capital.

The firm was established to address critical needs in oncology, particularly targeting KRAS mutations. The company's CEO, Perry Nisen, has extensive experience in the biotechnology sector, although details about previous companies he founded are not available. Quanta Therapeutics specializes in developing innovative allosteric inhibitors specifically targeting RAS-driven cancers, with a focus on KRAS mutations, which are implicated in nearly 25% of all cancers. Their primary product offerings include distinct small molecule inhibitors designed to target KRAS mutations, particularly the KRAS G12D and KRAS G12V variants.

Their lead candidates, QTX3034 and QTX3046, are currently undergoing Phase 1 clinical trials, aiming to address significant unmet needs within the oncology market by expanding treatment options beyond the currently available KRAS G12C inhibitors. Quanta Therapeutics operates within a framework focused on partnerships and collaborations to advance its pipeline of KRAS inhibitors. The company engages in Business-to-Business (B2B) transactions with pharmaceutical companies and research institutions, which may involve licensing agreements or co-development partnerships for their proprietary compounds. Revenue generation may stem from milestones achieved during clinical development phases, as well as potential royalties on sales post-commercialization of successful products.

Their flagship candidates, including the G12D-preferring multi-KRAS inhibitor QTX3034 and the G12V-preferring multi-KRAS inhibitor QTX3544, are critical to their revenue strategy, likely aiming to capture significant market share in the oncology therapeutics sector once they receive regulatory approval and enter the market. In May 2023, Quanta Therapeutics, Inc. raised USD 50. 68 mn in Series D funding to accelerate its lead programs' clinical trials and discover additional programs.

The company plans to develop new product offerings targeting additional KRAS mutations and expand its market presence, particularly in oncology. With the recent funding, Quanta aims to advance its clinical trials, which will facilitate the launch of its therapies and potentially enter new geographic regions for commercialization.